Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,capitalSurplus,totalLiab,totalStockholderEquity,otherCurrentLiab,totalAssets,commonStock,retainedEarnings,otherLiab,otherAssets,cash,totalCurrentLiabilities,propertyPlantEquipment,totalCurrentAssets,shortTermInvestments,netReceivables,accountsPayable,otherCurrentAssets,investments,changeToLiabilities,totalCashflowsFromInvestingActivities,totalCashFromFinancingActivities,changeToOperatingActivities,issuanceOfStock,changeInCash,repurchaseOfStock,totalCashFromOperatingActivities,depreciation,changeToAccountReceivables,otherCashflowsFromFinancingActivities,changeToNetincome,capitalExpenditures,WC,language,region,quoteType,triggerable,quoteSourceName,currency,market,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,shortName,exchange,marketState,twoHundredDayAverageChangePercent,exchangeDataDelayedBy,esgPopulated,tradeable,regularMarketChangePercent,regularMarketDayRange,regularMarketPreviousClose,bid,ask,bidSize,askSize,messageBoardId,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,earningsTimestamp,earningsTimestampStart,earningsTimestampEnd,epsTrailingTwelveMonths,epsForward,priceHint,epsCurrentYear,priceEpsCurrentYear,bookValue,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,marketCap,forwardPE,priceToBook,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,gmtOffSetMilliseconds,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,"Shares Short (May 27, 2021) 4","Short Ratio (May 27, 2021) 4","Short % of Float (May 27, 2021) 4","Short % of Shares Outstanding (May 27, 2021) 4","Shares Short (prior month Apr 29, 2021) 4",Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,compensationRisk,auditRisk,longBusinessSummary,city,phone,state,shareHolderRightsRisk,compensationAsOfEpochDate,governanceEpochDate,boardRisk,country,website,maxAge,overallRisk,address1,industry
t0,DRNA,126404000.0,76900096,56038000,,-29965000,,-29965000,20672000,47603000,-29107000,-29107000,,-4000,,,,0,47603000,76710000,0,-858000,,-29965000,-29965000,794424000.0,557006000.0,126404000.0,137954000.0,683410000.0,8000.0,-668028000.0,327288000.0,11007000.0,159111000.0,182147000.0,77903000.0,594500000.0,385773000.0,31267000.0,11276000.0,,56264000,-15219000,52886000,6158000,-3143000,7582000,32344000,-1414000,-26700000,821000,3446000,-10000,17360000,-3378000,412353000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,us_market,20.515,1630505868,-0.065000534,20.8,20.98,20.395,109989,"Dicerna Pharmaceuticals, Inc.",NMS,REGULAR,-0.31222776,0,False,False,-0.31584322,20.395 - 20.98,20.58,20.49,20.54,9,13,finmb_39280611,NasdaqGS,"Dicerna Pharmaceuticals, Inc.",USD,978415,1113383,4.0149994,0.2433333,16.5 - 40.14,-19.625,-0.4889138,16.5,40.14,1620331200,1635937140,1636372800,-1.602,-1.65,2,-1.82,-11.271977,1.651,29.980556,-9.465557,-0.31572318,29.828188,-9.313189,1577605376,-12.433333,12.425802,15,America/New_York,EDT,-14400000,1.08,,,40.14,16.5,29.98,29.83,978.41k,1.11M,76.9M,,63.84M,7.24%,84.67%,5.08M,7.04,6.90%,6.61%,5.72M,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",-67.58%,-65.86%,-10.02%,-79.01%,177.88M,2.37,39.90%,-41.08M,-114.65M,-120.22M,-1.60,,544.88M,7.09,51.64M,40.85,3.26,1.65,-172.67M,-138.75M,Value,02421,Healthcare,302,8,7,"Dicerna Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercializing of ribonucleic acid interference (RNAi)-based pharmaceuticals. The company develops pharmaceuticals using its GalXC RNAi platform for the treatment of diseases involving the liver, including rare, cardiometabolic, viral, and chronic liver diseases; complement-mediated diseases; and neurodegenerative diseases and pain. Its principal development programs include nedosiran for the treatment of primary hyperoxaluria; RG6346 for the treatment of chronic hepatitis B virus infection; belcesiran for the treatment of deficiency-associated liver disease; and DCR-AUD for the treatment of alcohol use disorder. Dicerna Pharmaceuticals, Inc. has strategic collaborations with Novo Nordisk A/S, F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., Eli Lilly and Company, Alnylam Pharmaceuticals, Inc., Alexion Pharmaceuticals, Inc., and Boehringer Ingelheim International GmbH. The company was incorporated in 2006 and is headquartered in Lexington, Massachusetts.",Lexington,617 621 8097,MA,1,1609372800,1622505600,5,United States,http://dicerna.com,86400,4,75 Hayden Avenue,Biotechnology
t-1,DRNA,137754000.0,76900096,56038000,,-36586000,,-36586000,18582000,-13067000,-31649000,-31649000,,-20000,,,,0,40956000,72605000,54023000,-4937000,,-36586000,-36586000,775809000.0,570092000.0,137754000.0,138537000.0,707846000.0,8000.0,-638063000.0,343410000.0,10754000.0,126023000.0,177938000.0,78389000.0,618703000.0,442820000.0,36058000.0,7901000.0,744000.0,-37725000,7041000,-41978000,11023000,-6914000,11034000,-78258000,-1414000,-47303000,604000,-29685000,-11000,18237000,-4253000,440765000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,us_market,20.515,1630505868,-0.065000534,20.8,20.98,20.395,109989,"Dicerna Pharmaceuticals, Inc.",NMS,REGULAR,-0.31222776,0,False,False,-0.31584322,20.395 - 20.98,20.58,20.49,20.54,9,13,finmb_39280611,NasdaqGS,"Dicerna Pharmaceuticals, Inc.",USD,978415,1113383,4.0149994,0.2433333,16.5 - 40.14,-19.625,-0.4889138,16.5,40.14,1620331200,1635937140,1636372800,-1.602,-1.65,2,-1.82,-11.271977,1.651,29.980556,-9.465557,-0.31572318,29.828188,-9.313189,1577605376,-12.433333,12.425802,15,America/New_York,EDT,-14400000,1.08,,,40.14,16.5,29.98,29.83,978.41k,1.11M,76.9M,,63.84M,7.24%,84.67%,5.08M,7.04,6.90%,6.61%,5.72M,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",-67.58%,-65.86%,-10.02%,-79.01%,177.88M,2.37,39.90%,-41.08M,-114.65M,-120.22M,-1.60,,544.88M,7.09,51.64M,40.85,3.26,1.65,-172.67M,-138.75M,Value,02421,Healthcare,302,8,7,"Dicerna Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercializing of ribonucleic acid interference (RNAi)-based pharmaceuticals. The company develops pharmaceuticals using its GalXC RNAi platform for the treatment of diseases involving the liver, including rare, cardiometabolic, viral, and chronic liver diseases; complement-mediated diseases; and neurodegenerative diseases and pain. Its principal development programs include nedosiran for the treatment of primary hyperoxaluria; RG6346 for the treatment of chronic hepatitis B virus infection; belcesiran for the treatment of deficiency-associated liver disease; and DCR-AUD for the treatment of alcohol use disorder. Dicerna Pharmaceuticals, Inc. has strategic collaborations with Novo Nordisk A/S, F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., Eli Lilly and Company, Alnylam Pharmaceuticals, Inc., Alexion Pharmaceuticals, Inc., and Boehringer Ingelheim International GmbH. The company was incorporated in 2006 and is headquartered in Lexington, Massachusetts.",Lexington,617 621 8097,MA,1,1609372800,1622505600,5,United States,http://dicerna.com,86400,4,75 Hayden Avenue,Biotechnology
t-2,DRNA,153700000.0,76900096,56038000,,-21849000,,-21849000,16961000,-5939000,-22900000,-22900000,,-20000,,,,0,48875000,71775000,54814000,1051000,,-21849000,-21849000,755170000.0,528038000.0,153700000.0,200041000.0,681738000.0,7000.0,-601477000.0,269110000.0,13105000.0,204281000.0,239768000.0,40982000.0,627651000.0,405632000.0,5981000.0,7249000.0,,65638000,-44327000,61502000,2786000,1020000,2796000,7279000,-1414000,-57009000,547000,-5016000,-10000,12616000,-4136000,387883000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,us_market,20.515,1630505868,-0.065000534,20.8,20.98,20.395,109989,"Dicerna Pharmaceuticals, Inc.",NMS,REGULAR,-0.31222776,0,False,False,-0.31584322,20.395 - 20.98,20.58,20.49,20.54,9,13,finmb_39280611,NasdaqGS,"Dicerna Pharmaceuticals, Inc.",USD,978415,1113383,4.0149994,0.2433333,16.5 - 40.14,-19.625,-0.4889138,16.5,40.14,1620331200,1635937140,1636372800,-1.602,-1.65,2,-1.82,-11.271977,1.651,29.980556,-9.465557,-0.31572318,29.828188,-9.313189,1577605376,-12.433333,12.425802,15,America/New_York,EDT,-14400000,1.08,,,40.14,16.5,29.98,29.83,978.41k,1.11M,76.9M,,63.84M,7.24%,84.67%,5.08M,7.04,6.90%,6.61%,5.72M,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",-67.58%,-65.86%,-10.02%,-79.01%,177.88M,2.37,39.90%,-41.08M,-114.65M,-120.22M,-1.60,,544.88M,7.09,51.64M,40.85,3.26,1.65,-172.67M,-138.75M,Value,02421,Healthcare,302,8,7,"Dicerna Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercializing of ribonucleic acid interference (RNAi)-based pharmaceuticals. The company develops pharmaceuticals using its GalXC RNAi platform for the treatment of diseases involving the liver, including rare, cardiometabolic, viral, and chronic liver diseases; complement-mediated diseases; and neurodegenerative diseases and pain. Its principal development programs include nedosiran for the treatment of primary hyperoxaluria; RG6346 for the treatment of chronic hepatitis B virus infection; belcesiran for the treatment of deficiency-associated liver disease; and DCR-AUD for the treatment of alcohol use disorder. Dicerna Pharmaceuticals, Inc. has strategic collaborations with Novo Nordisk A/S, F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., Eli Lilly and Company, Alnylam Pharmaceuticals, Inc., Alexion Pharmaceuticals, Inc., and Boehringer Ingelheim International GmbH. The company was incorporated in 2006 and is headquartered in Lexington, Massachusetts.",Lexington,617 621 8097,MA,1,1609372800,1622505600,5,United States,http://dicerna.com,86400,4,75 Hayden Avenue,Biotechnology
t-3,DRNA,162168000.0,76900096,56038000,,-31820000,,-31820000,20565000,-12928000,-33493000,-33493000,,-6000,,,,0,40448000,73941000,53376000,1673000,,-31820000,-31820000,741789000.0,570242000.0,162168000.0,221343000.0,732410000.0,7000.0,-579628000.0,291497000.0,12025000.0,197801000.0,258926000.0,38623000.0,681762000.0,471408000.0,1339000.0,7764000.0,,-9886000,-37753000,-11864000,5846000,405000,5962000,-47678000,-1414000,-41660000,531000,14988000,-116000,11989000,-1978000,422836000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,us_market,20.515,1630505868,-0.065000534,20.8,20.98,20.395,109989,"Dicerna Pharmaceuticals, Inc.",NMS,REGULAR,-0.31222776,0,False,False,-0.31584322,20.395 - 20.98,20.58,20.49,20.54,9,13,finmb_39280611,NasdaqGS,"Dicerna Pharmaceuticals, Inc.",USD,978415,1113383,4.0149994,0.2433333,16.5 - 40.14,-19.625,-0.4889138,16.5,40.14,1620331200,1635937140,1636372800,-1.602,-1.65,2,-1.82,-11.271977,1.651,29.980556,-9.465557,-0.31572318,29.828188,-9.313189,1577605376,-12.433333,12.425802,15,America/New_York,EDT,-14400000,1.08,,,40.14,16.5,29.98,29.83,978.41k,1.11M,76.9M,,63.84M,7.24%,84.67%,5.08M,7.04,6.90%,6.61%,5.72M,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",-67.58%,-65.86%,-10.02%,-79.01%,177.88M,2.37,39.90%,-41.08M,-114.65M,-120.22M,-1.60,,544.88M,7.09,51.64M,40.85,3.26,1.65,-172.67M,-138.75M,Value,02421,Healthcare,302,8,7,"Dicerna Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercializing of ribonucleic acid interference (RNAi)-based pharmaceuticals. The company develops pharmaceuticals using its GalXC RNAi platform for the treatment of diseases involving the liver, including rare, cardiometabolic, viral, and chronic liver diseases; complement-mediated diseases; and neurodegenerative diseases and pain. Its principal development programs include nedosiran for the treatment of primary hyperoxaluria; RG6346 for the treatment of chronic hepatitis B virus infection; belcesiran for the treatment of deficiency-associated liver disease; and DCR-AUD for the treatment of alcohol use disorder. Dicerna Pharmaceuticals, Inc. has strategic collaborations with Novo Nordisk A/S, F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., Eli Lilly and Company, Alnylam Pharmaceuticals, Inc., Alexion Pharmaceuticals, Inc., and Boehringer Ingelheim International GmbH. The company was incorporated in 2006 and is headquartered in Lexington, Massachusetts.",Lexington,617 621 8097,MA,1,1609372800,1622505600,5,United States,http://dicerna.com,86400,4,75 Hayden Avenue,Biotechnology
